Drug Profile
[18F] JNJ 64511070
Alternative Names: 18F JNJ 64511070Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(Diagnosis, In volunteers) in Belgium (IV, Injection)
- 01 Sep 2020 Enigma Biomedical Group plans a preclinical and clinical studies in Neurodegenerative disorders including Alzheimer’s disease and other dementias
- 01 Sep 2020 Enigma Biomedical Group enters into a license and option agreement with Janssen Pharmaceutica for neuroimaging biomarkers